MBX Biosciences, Inc. Increase (Decrease) in Accrued Liabilities
MBX Biosciences, Inc. (MBX) reported Increase (Decrease) in Accrued Liabilities of $6.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-06
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $11.20M.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.86M, a 970.43% decline year-over-year.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $4.45M.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $2.04M, a 77.37% increase year-over-year.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $6.80M, a 114.32% increase from fiscal 2024.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $3.17M, a 6946.67% increase from fiscal 2023.
- MBX Biosciences, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $45.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.34M 10-Q · filed 2026-08-06 | $10.79M derived: sum of 3 quarters · filed 2026-08-06 | $12.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.86M 10-Q · filed 2026-05-07 | -$404.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.63M derived: sum of 3 quarters · filed 2026-05-07 | $1.38M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.49M derived: sum of 2 quarters · filed 2026-03-12 | $6.24M derived: sum of 3 quarters · filed 2026-08-06 | $6.80M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.78M derived: sum of 2 quarters · filed 2026-08-06 | $2.34M 10-Q · filed 2025-11-06 | $2.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$253.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $305.00K 10-Q · filed 2026-08-06 | $102.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $558.00K 10-Q · filed 2026-05-07 | $355.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.50M derived: sum of 3 quarters · filed 2026-05-07 | $4.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$203.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $946.00K derived: sum of 2 quarters · filed 2026-03-12 | $3.58M derived: sum of 3 quarters · filed 2026-03-12 | $3.17M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.79M derived: sum of 2 quarters · filed 2025-11-06 | $3.37M 10-Q · filed 2025-11-06 | $2.19M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.23M 10-Q · filed 2025-08-07 | $1.04M derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | -$411.00K 10-Q · filed 2025-05-12 | -$1.59M derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $45.00K 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $1.23M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |